With the success of the in vitro studies, we can extrapolate that nano-encapsulated drugs such as indomethacin may hopefully be able to target the COX2 and POX active sites, while VEGF-containing nanoparticles may lead to the cascade of remodeling process necessary for anatomical PDA closure. The gene discussed is PRODH; the disease is Patent ductus arteriosus.